Piqray

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Alpelisib

Available from:

Novartis Europharm Limited 

ATC code:

L01XE

INN (International Name):

alpelisib

Therapeutic group:

Aġenti antineoplastiċi

Therapeutic area:

Neoplażmi tas-Sider

Therapeutic indications:

Piqray huwa indikat, flimkien ma 'fulvestrant għall-kura ta' nisa wara l-menopawża, u l-irġiel, bl-ormon tat-riċettur (HR)-pożittivi, tal-bniedem tar-riċettur tal-fattur tat-tkabbir epidermali 2 (HER2)-negattivi, lokalment avvanzat jew dak metastatiku-kanċer tas-sider bil-PIK3CA mutazzjoni wara l-progressjoni tal-marda wara l-terapija endokrinali bħala monoterapija (ara sezzjoni 5.

Product summary:

Revision: 10

Authorization status:

Awtorizzat

Authorization date:

2020-07-27

Patient Information leaflet

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
Piqray 50 mg pilloli miksijin b’rita
Piqray 150 mg pilloli miksijin b’rita
Piqray 200 mg pilloli miksijin b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Piqray 50 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 50 mg ta’ alpelisib.
Piqray 150 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 150 mg ta’ alpelisib.
Piqray 200 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 200 mg ta’ alpelisib.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola).
Piqray 50 mg pilloli miksijin b’rita
Pillola miksija b’rita, roża ċara, tonda, ġejja għat-tond,
b’xifer imżerżaq, ittimbrata b’“L7” fuq naħa
waħda u “NVR” fuq in-naħa l-oħra. Dijametru approssimattiv: 7.2
mm.
Piqray 150 mg pilloli miksijin b’rita
Pillola miksija b’rita, ħamra ċassa, ovali, b’għamla li tagħti
fit-tond b’xifer imżerżaq, ittimbrata
b’“UL7” fuq naħa waħda u “NVR” fuq in-naħa l-oħra. Daqs
approssimattiv: 14.2 mm (tul); 5.7 mm
(wisa’).
Piqray 200 mg pilloli miksijin b’rita
Pillola miksija b’rita, ħamra ċara, ovali, b’għamla li tagħti
fit-tond b’xifer imżerżaq, ittimbrata
b’“YL7” fuq naħa waħda u “NVR” fuq in-naħa l-oħra. Daqs
approssimattiv: 16.2 mm (tul); 6.5 mm
(wisa’).
3
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Piqray huwa indikat flimkien ma’ fulvestrant għat-trattament ta’
nisa wara l-menopawża, u rġiel, bir-
riċettur tal-ormoni (HR) pożittiv, riċettur 2 tal-fattur
tat-tkabbir epidermiku tal-bniedem (
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
Piqray 50 mg pilloli miksijin b’rita
Piqray 150 mg pilloli miksijin b’rita
Piqray 200 mg pilloli miksijin b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Piqray 50 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 50 mg ta’ alpelisib.
Piqray 150 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 150 mg ta’ alpelisib.
Piqray 200 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 200 mg ta’ alpelisib.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola).
Piqray 50 mg pilloli miksijin b’rita
Pillola miksija b’rita, roża ċara, tonda, ġejja għat-tond,
b’xifer imżerżaq, ittimbrata b’“L7” fuq naħa
waħda u “NVR” fuq in-naħa l-oħra. Dijametru approssimattiv: 7.2
mm.
Piqray 150 mg pilloli miksijin b’rita
Pillola miksija b’rita, ħamra ċassa, ovali, b’għamla li tagħti
fit-tond b’xifer imżerżaq, ittimbrata
b’“UL7” fuq naħa waħda u “NVR” fuq in-naħa l-oħra. Daqs
approssimattiv: 14.2 mm (tul); 5.7 mm
(wisa’).
Piqray 200 mg pilloli miksijin b’rita
Pillola miksija b’rita, ħamra ċara, ovali, b’għamla li tagħti
fit-tond b’xifer imżerżaq, ittimbrata
b’“YL7” fuq naħa waħda u “NVR” fuq in-naħa l-oħra. Daqs
approssimattiv: 16.2 mm (tul); 6.5 mm
(wisa’).
3
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Piqray huwa indikat flimkien ma’ fulvestrant għat-trattament ta’
nisa wara l-menopawża, u rġiel, bir-
riċettur tal-ormoni (HR) pożittiv, riċettur 2 tal-fattur
tat-tkabbir epidermiku tal-bniedem (
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-10-2023
Public Assessment Report Public Assessment Report Bulgarian 30-07-2020
Patient Information leaflet Patient Information leaflet Spanish 26-10-2023
Public Assessment Report Public Assessment Report Spanish 30-07-2020
Patient Information leaflet Patient Information leaflet Czech 26-10-2023
Public Assessment Report Public Assessment Report Czech 30-07-2020
Patient Information leaflet Patient Information leaflet Danish 26-10-2023
Public Assessment Report Public Assessment Report Danish 30-07-2020
Patient Information leaflet Patient Information leaflet German 26-10-2023
Public Assessment Report Public Assessment Report German 30-07-2020
Patient Information leaflet Patient Information leaflet Estonian 26-10-2023
Public Assessment Report Public Assessment Report Estonian 30-07-2020
Patient Information leaflet Patient Information leaflet Greek 26-10-2023
Public Assessment Report Public Assessment Report Greek 30-07-2020
Patient Information leaflet Patient Information leaflet English 26-10-2023
Public Assessment Report Public Assessment Report English 30-07-2020
Patient Information leaflet Patient Information leaflet French 26-10-2023
Public Assessment Report Public Assessment Report French 30-07-2020
Patient Information leaflet Patient Information leaflet Italian 26-10-2023
Public Assessment Report Public Assessment Report Italian 30-07-2020
Patient Information leaflet Patient Information leaflet Latvian 26-10-2023
Public Assessment Report Public Assessment Report Latvian 30-07-2020
Patient Information leaflet Patient Information leaflet Lithuanian 26-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-10-2023
Public Assessment Report Public Assessment Report Lithuanian 30-07-2020
Patient Information leaflet Patient Information leaflet Hungarian 26-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 26-10-2023
Public Assessment Report Public Assessment Report Hungarian 30-07-2020
Patient Information leaflet Patient Information leaflet Dutch 26-10-2023
Public Assessment Report Public Assessment Report Dutch 30-07-2020
Patient Information leaflet Patient Information leaflet Polish 26-10-2023
Public Assessment Report Public Assessment Report Polish 30-07-2020
Patient Information leaflet Patient Information leaflet Portuguese 26-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 26-10-2023
Public Assessment Report Public Assessment Report Portuguese 30-07-2020
Patient Information leaflet Patient Information leaflet Romanian 26-10-2023
Public Assessment Report Public Assessment Report Romanian 30-07-2020
Patient Information leaflet Patient Information leaflet Slovak 26-10-2023
Public Assessment Report Public Assessment Report Slovak 30-07-2020
Patient Information leaflet Patient Information leaflet Slovenian 26-10-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 26-10-2023
Public Assessment Report Public Assessment Report Slovenian 30-07-2020
Patient Information leaflet Patient Information leaflet Finnish 26-10-2023
Public Assessment Report Public Assessment Report Finnish 30-07-2020
Patient Information leaflet Patient Information leaflet Swedish 26-10-2023
Public Assessment Report Public Assessment Report Swedish 30-07-2020
Patient Information leaflet Patient Information leaflet Norwegian 26-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 26-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 26-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 26-10-2023
Patient Information leaflet Patient Information leaflet Croatian 26-10-2023
Public Assessment Report Public Assessment Report Croatian 30-07-2020

Search alerts related to this product

View documents history